Extended use of real-time continuous glucose monitoring in adults with insulin-requiring type 2 diabetes: Results from the first 26 weeks of the 2GO-CGM trial.

ABSTRACT:

Aims

The first 26 weeks of the 2GO-CGM trial assessed the efficacy and safety of real-time continuous glucose monitoring (rtCGM) use within a supported specialist model of care in a cohort of community-based adults with insulin-requiring type 2 diabetes in New Zealand.

Methods

A 26-week randomised one-way crossover 'waitlist-controlled' trial comparing rtCGM (Dexcom G6) with self-monitoring of blood glucose (SMBG). All participants completed 2 weeks of SMBG before being randomised to 12 weeks (phase 1) use of SMBG followed by 12 weeks (phase 2) use of rtCGM (Group A) or 24 weeks of rtCGM (Group B). A time-adjusted within_-subject analysis was conducted to estimate the overall treatment effect of rtCGM versus SMBG.

Results

Sixty-seven participants were random

SUBMITTER: Lever CS 

PROVIDER: S-EPMC12006558 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature